Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

被引:72
作者
Green, Alexa S. [1 ,2 ,3 ,4 ]
Maciel, Thiago T. [5 ,6 ,7 ,8 ]
Hospital, Marie-Anne [1 ,2 ,3 ]
Yin, Chae [9 ]
Mazed, Fetta [1 ,2 ,3 ]
Townsend, Elizabeth C. [10 ]
Pilorge, Sylvain [1 ,2 ,3 ,11 ]
Lambert, Mireille [1 ,2 ,3 ]
Paubelle, Etienne [5 ,6 ,7 ,8 ]
Jacquel, Arnaud [11 ]
Zylbersztejn, Florence [5 ,6 ,7 ,8 ]
Decroocq, Justine [5 ,6 ,7 ,8 ]
Poulain, Laury [1 ,2 ,3 ]
Sujobert, Pierre [1 ,2 ,3 ]
Jacque, Nathalie [1 ,2 ,3 ]
Adam, Kevin [1 ,2 ,3 ]
So, Jason C. C. [9 ]
Kosmider, Olivier [1 ,2 ,3 ]
Auberger, Patrick [11 ]
Hermine, Olivier [5 ,6 ,7 ,8 ]
Weinstock, David M. [10 ]
Lacombe, Catherine [1 ,2 ,3 ]
Mayeux, Patrick [1 ,2 ,3 ]
Vanasse, Gary J. [12 ]
Leung, Anskar Y. [9 ]
Moura, Ivan C. [5 ,6 ,7 ,8 ]
Bouscary, Didier [1 ,2 ,3 ]
Tamburini, Jerome [1 ,2 ,3 ]
机构
[1] CNRS, Inst Cochin, INSERM U1016, Dept Dev Reprod Canc,UMR 8104, F-75014 Paris, France
[2] Univ Paris 05, Fac Med, Sorbonne Paris Cite, F-75005 Paris, France
[3] Ligue Natl Canc LNCC, Equipe Labellisee, F-75013 Paris, France
[4] Charles Nicolle Univ Hosp, Dept Hematol, F-76000 Rouen, France
[5] INSERM UMR 1163, Lab Cellular & Mol Mech Hematol Disorders & Thera, F-75015 Paris, France
[6] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, F-75015 Paris, France
[7] CNRS, ERL 8254, F-75015 Paris, France
[8] Lab Excellence GR Ex, F-75015 Paris, France
[9] Univ Hong Kong, Li Ka Shing LKS Fac Med, Dept Med, Div Hematol, Hong Kong, Hong Kong, Peoples R China
[10] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[11] INSERM U1065, C3M Team 2, Cell Death Differentiat Inflammat & Canc, F-06204 Nice, France
[12] Novartis Inst BioMed Res, Cambridge, MA 02139 USA
来源
SCIENCE ADVANCES | 2015年 / 1卷 / 08期
关键词
Compilation and indexing terms; Copyright 2025 Elsevier Inc;
D O I
10.1126/sciadv.1500221
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide shortterm disease control, but relapse invariably occurs within months. Pim protein kinases are oncogenic FLT3-ITD targets expressed in AML cells. We show that increased Pim kinase expression is found in relapse samples from AML patients treated with FLT3 inhibitors. Ectopic Pim-2 expression induces resistance to FLT3 inhibition in both FLT3ITD- induced myeloproliferative neoplasm and AML models in mice. Strikingly, we found that Pim kinases govern FLT3-ITD signaling and that their pharmacological or genetic inhibition restores cell sensitivity to FLT3 inhibitors. Finally, dual inhibition of FLT3 and Pimkinases eradicates FLT3-ITD+ cells including primary AML cells. Concomitant Pim and FLT3 inhibition represents a promising new avenue for AML therapy.
引用
收藏
页数:13
相关论文
empty
未找到相关数据